About 24 results found for searched term "BTK IN-1" (0.182 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M20631 | BTK inhibitor 1 (Compound 27) | BTK |
| BTK inhibitor 1 (compound 27) is an inhibitor of BTK with an IC50 of 0.11 nM for Btk and inhibits B cell activation in hWB with an IC50 of 2 nM. | ||
| M28101 | BTK IN-1 | BTK |
| SNS062 analog | ||
| BTK IN-1 (SNS062 analog) is a potent BTK inhibitor, with an IC50 of <100 nM. | ||
| M28957 | BTK inhibitor 17 | BTK |
| BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research. | ||
| M49587 | JAK3/BTK-IN-1 | JAK |
| JAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. | ||
| M2536 | CNX-774 | BTK |
| CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM. | ||
| M43813 | NX-2127 | BTK |
| NX-2127 is an orally active, potent BTK inhibitor that induces degradation of mutant BTKC481S in cells, as well as inhibits the proliferation of BTKC481S mutant TMD8 cells. In addition, NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells. | ||
| M8887 | Btk inhibitor 2 | BTK |
| BGB-3111 | ||
| Btk inhibitor 2 (BGB-3111) is a Brutons tyrosine kinase (BTK) inhibitor. | ||
| M8941 | GDC-0853 (Fenebrutinib) | BTK |
| Fenebrutinib; RG7845 | ||
| GDC-0853 (Fenebrutinib) is a potent, selective and non-covalent bruton tyrosine kinase (Btk) inhibitor with a Ki value of 0.91 nM against BRK. | ||
| M10500 | Remibrutinib (LOU064) | BTK |
| LOU064 | ||
| Remibrutinib (LOU064) is a potentially best-in-class "best-in-class" orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM and an IC50 value of 0.23 μM for inhibition of BTK activity in blood. Remibrutinib can be used to study chronic urticaria (CU). | ||
| M11431 | Poseltinib | BTK |
| HM71224; LY3337641 | ||
| Poseltinib is an orally active, selective, irreversible small-molecule Bruton tyrosine kinase (BTK) inhibitor with an IC50 of 1.95 nM and 0.3, 2.3, and 2.4 fold selective action against BMX, TEC, and TXK, respectively. Poseltinib covalently binds to the active site of BTK (cysteine 481 residue) and effectively inhibits B cell receptor (BCR), Fc receptor (FcR), and Toll-like receptor (TLR) mediated signaling. | ||
| M21222 | BIIB091 | BTK |
| The reversible BTK kinase inhibitor BIIB091 is a highly selective phase I clinical candidate compound for multiple sclerosis. | ||
| M28627 | Atuzabrutinib | BTK |
| SAR 444727; PRN473 | ||
| Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling. | ||
| M28664 | PF-06250112 | BTK |
| PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively. | ||
| M28767 | Elsubrutinib | BTK |
| ABBV-105 | ||
| Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor。The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease. | ||
| M28865 | BIIB068 | BTK |
| BIIB068 is a potent, selective, reversible and orally active BTK inhibitor with an IC50 of 1 nM and a Kd of 0.3 nM. BIIB068 shows more >400-fold selective for BTK than other kinases. BIIB068 has the potential for autoimmune diseases research. | ||
| M29210 | CHMFL-BTK-01 | BTK |
| CHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation. | ||
| M29440 | TL12-186 | PROTAC |
| TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A (IC50=73 nM) and CDK9/cyclin T1 (IC50=55 nM). | ||
| M29480 | BGB-8035 | BTK |
| BGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with IC50s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research. | ||
| M29609 | JS25 | BTK |
| JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC50 value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier. | ||
| M30952 | Lck inhibitor 2 | Src-bcr-Abl |
| Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively IC50 Value: 13 nM(Lck) [1] Target: Src family kinase Lck inhibitor 2(Compound 9) inhibited 48 kinases with %control < 1 (33 of them tyrosine kinases, almost half of the 71 tyrosine kinases in the panel). A further 27 kinases were bound with %control < 10. Kd values for 16 kinases were determined and found to be below 100 nM. These included TXK (10 nM). | ||
| M43472 | BTK-IN-26 | BTK |
| BTK-IN-26 is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC50 values of 0.7 and 0.8 nM for BTK and BTK C481S, respectively. | ||
| M43474 | BTK-IN-25 | BTK |
| BTK-IN-25 is a potent inhibitor of BTK, and inhibits BTK(C481S) with an IC50 value of 0.77 nM. | ||
| M43475 | PROTAC BTK Degrader-5 | BTK |
| PROTAC BTK degraders-5is a selective BTK degrader with a DC50 value of 7.0 nM in JeKo-1 cells. | ||
| M45374 | Terreic acid | Senolytics |
| Terreic acid is a quinone epoxide antibiotic and a potent Btk inhibitor, blocking the interaction between PKC and the PH domain of Btk.T Terreic acid also acts on HMC-1 human mast cell lysates, inhibiting the binding of GST-BtkPH to PKC with an IC50 of approximately 100 μM. Terreic acid also acts on HMC-1 human mast cell lysates to inhibit the binding of GST-BtkPH to PKC, with an IC50 of approximately 100 μM. In addition, Terreic acid simultaneously reduces the percentage of senescent cells and SASP expression in cells exposed to stress stimuli. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
